Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Manseau MW, Goff DC.

Neurotherapeutics. 2015 Aug 27. [Epub ahead of print]

PMID:
26311150
2.

Risks associated with the non-medicinal use of cannabis.

Hoch E, Bonnetn U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW.

Dtsch Arztebl Int. 2015 Apr 17;112(16):271-8. doi: 10.3238/arztebl.2015.0271.

3.

The Psychosis-like Effects of Δ<sup>9</sup>-Tetrahydrocannabinol Are Associated with Increased Cortical Noise in Healthy Humans.

Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D'Souza DC.

Biol Psychiatry. 2015 Mar 30. pii: S0006-3223(15)00269-3. doi: 10.1016/j.biopsych.2015.03.023. [Epub ahead of print]

PMID:
25913109
4.

Need for a comprehensive national survey of cannabis use.

Hamilton I.

BMJ. 2015 Mar 30;350:h1668. doi: 10.1136/bmj.h1668. No abstract available.

PMID:
25825416
5.

Impact of Cannabis Use on the Development of Psychotic Disorders.

Wilkinson ST, Radhakrishnan R, D'Souza DC.

Curr Addict Rep. 2014 Jun 1;1(2):115-128.

6.

High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis.

Hall W, Degenhardt L.

BMJ. 2015 Mar 4;350:h1205. doi: 10.1136/bmj.h1205. No abstract available.

PMID:
25739398
7.

Δ(9)-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.

Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D'Souza DC.

Neuropsychopharmacology. 2015 Aug;40(9):2124-34. doi: 10.1038/npp.2015.53. Epub 2015 Apr 24.

PMID:
25709097
8.

Use of synthetic cannabinoids in patients with psychotic disorders: case series.

Celofiga A, Koprivsek J, Klavz J.

J Dual Diagn. 2014;10(3):168-73. doi: 10.1080/15504263.2014.929364.

PMID:
25392292
9.

How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia.

Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, Slater M, Godlewska B, Cornish R, Williams J, Di Simplicio M, Igoumenou A, Brenneisen R, Tunbridge EM, Harrison PJ, Harmer CJ, Cowen P, Morrison PD.

Schizophr Bull. 2015 Mar;41(2):391-9. doi: 10.1093/schbul/sbu098. Epub 2014 Jul 15.

10.

[Short-and long-term effects of cannabinoids on memory, cognition and mental illness].

Sagie S, Eliasi Y, Livneh I, Bart Y, Monovich E.

Harefuah. 2013 Dec;152(12):737-41, 751. Review. Hebrew.

PMID:
24483000
11.

Genetic dissection of the psychotomimetic effects of cannabinoid exposure.

O'Tuathaigh CM, Gantois I, Waddington JL.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:33-40. doi: 10.1016/j.pnpbp.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24239593
12.

Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats.

Zamberletti E, Beggiato S, Steardo L Jr, Prini P, Antonelli T, Ferraro L, Rubino T, Parolaro D.

Neurobiol Dis. 2014 Mar;63:35-47. doi: 10.1016/j.nbd.2013.10.028. Epub 2013 Nov 4.

PMID:
24200867
13.

Cannabis Use during Adolescent Development: Susceptibility to Psychiatric Illness.

Chadwick B, Miller ML, Hurd YL.

Front Psychiatry. 2013 Oct 14;4:129. doi: 10.3389/fpsyt.2013.00129. Review.

14.

Therapeutic potential of cannabinoid medicines.

Robson PJ.

Drug Test Anal. 2014 Jan-Feb;6(1-2):24-30. doi: 10.1002/dta.1529. Epub 2013 Sep 4. Review.

PMID:
24006213
15.

Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study.

Kuepper R, Ceccarini J, Lataster J, van Os J, van Kroonenburgh M, van Gerven JM, Marcelis M, Van Laere K, Henquet C.

PLoS One. 2013 Jul 25;8(7):e70378. doi: 10.1371/journal.pone.0070378. Print 2013.

16.

Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review.

Baldacchino A, Hughes Z, Kehoe M, Blair H, Teh Y, Windeatt S, Crome IB.

Am J Addict. 2012 Nov;21 Suppl 1:S88-98. doi: 10.1111/j.1521-0391.2012.00295.x. Review.

PMID:
23786516
17.

Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.

Gomes FV, Del Bel EA, Guimarães FS.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:43-7. doi: 10.1016/j.pnpbp.2013.06.005. Epub 2013 Jun 19.

18.

Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis.

Chan WL, Wood DM, Hudson S, Dargan PI.

J Med Toxicol. 2013 Sep;9(3):278-81. doi: 10.1007/s13181-013-0306-y.

19.

Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms.

Morgan CJ, Page E, Schaefer C, Chatten K, Manocha A, Gulati S, Curran HV, Brandner B, Leweke FM.

Br J Psychiatry. 2013 May;202(5):381-2. doi: 10.1192/bjp.bp.112.121178. Epub 2013 Apr 11.

20.

Cannabis, psychosis and the thalamus: a theoretical review.

Vukadinovic Z, Herman MS, Rosenzweig I.

Neurosci Biobehav Rev. 2013 May;37(4):658-67. doi: 10.1016/j.neubiorev.2013.02.013. Epub 2013 Feb 28. Review.

PMID:
23458778
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk